Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer.

被引：0
|
作者：
Pachynski, Russell Kent
Iannotti, Nicholas
Laccetti, Andrew Leonard
Carthon, Bradley Curtis
Chi, Kim N.
Smith, Matthew Raymond
Vogelzang, Nicholas J.
Tu, Wilson
Kwan, Edmond Michael
Wyatt, Alexander William
Villaluna, Karen
Younginger, Brett
Cesano, Alessandra
机构：
[1] Washington Univ Sch Med, St Louis, MO USA
[2] Treasure Coast, Hematol Oncol Assoc, Port St Lucie, FL USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[5] Vancouver Ctr, BC Canc, Vancouver, BC, Canada
[6] Massachusetts Gen Hosp, Boston, MA USA
[7] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[8] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada
[9] Essa Pharmaceut, South San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
177
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [22] Management of Metastatic Castration-Resistant Prostate Cancer
    Srinivas, Sandy
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 614 - 616
  • [23] Cabazitaxel in metastatic castration-resistant prostate cancer
    Yap, Timothy A.
    Pezaro, Carmel J.
    de Bono, Johann S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1129 - 1136
  • [24] Rucaparib in castration-resistant, metastatic prostate cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2024, 55 (02) : 96 - 98
  • [25] SPOP mutation as a predictive marker for treatment of metastatic castration-resistant prostate cancer.
    Stangl, Andrew
    Willner, Christopher
    Maahs, Lucas
    Burmeister, Charlotte
    Hwang, Clara
    Pilling, Amanda
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [26] Metastatic castration-resistant prostate cancer. Position paper for structured therapy monitoring
    Miller, K.
    Albers, P.
    Eichenauer, R.
    Geiges, G.
    Grimm, M. -O.
    Koenig, F.
    Mickisch, G.
    Pfister, D.
    Schwentner, C.
    Suttmann, H.
    Zastrow, S.
    UROLOGE, 2014, 53 (05): : 710 - 714
  • [27] The association of BMI and PSA density on survival among patients with metastatic or castration-resistant prostate cancer.
    Glaser, Zachary A.
    Avulova, Svetlana
    Stocks, Blair
    Penson, David F.
    Moses, Kelvin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [28] Salvage chemotherapy with cisplatin, ifosfamide, and paclitaxel in metastatic castration-resistant prostate cancer.
    Von Amsberg, Gunhild
    Zilles, Mirjam
    Gild, Philipp
    Alsdorf, Winfried
    Boeckelmann, Lukas
    Langebrake, Claudia
    Oh-Hohenhorst, Su Jung
    Tilki, Derya
    Graefen, Markus
    Dyshlovoy, Sergey
    Bokemeyer, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [29] Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
    Lin, Ting-Ting
    Chen, Ye-Hui
    Wu, Yu-Peng
    Chen, Shao-Zhan
    Li, Xiao-Dong
    Lin, Yun-Zhi
    Chen, Shao-Hao
    Zheng, Qing-Shui
    Wei, Yong
    Xu, Ning
    Xue, Xue-Yi
    JOURNAL OF CANCER, 2019, 10 (22): : 5608 - 5613
  • [30] Lipidomic profiling in patients with heavily pretreated castration-resistant prostate cancer.
    Cattrini, Carlo
    Manfredi, Marcello
    Barboro, Paola
    Ghirimoldi, Marco
    Mennitto, Alessia
    Martini, Veronica
    Biello, Federica
    D'Avanzo, Francesca
    Platini, Francesca
    Maggiora, Paola Maria
    Branni, Carmen
    Rua, Alessia
    Diprima, Santo
    Tassone, Andrea
    Gobbato, Simone
    Stella, Arianna
    Zanardi, Elisa
    Pinato, David James
    Boccardo, Francesco
    Gennari, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345